Drug Profile
Mibampator
Alternative Names: LY-451395Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Antidementias; Biphenyl compounds; Neuroprotectants; Small molecules; Sulfonamides
- Mechanism of Action AMPA receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Aggression; Agitation
Most Recent Events
- 16 Mar 2009 Eli Lilly and Company initiates enrolment in a phase II trial for Alzheimer's disease in USA